https://www.science.org/content/blog-post/had-enough-eh https://www.science.org/content/blog-post/had-enough-eh Less than a week ago ANOTHER amyloid hypothesis

https://www.science.org/content/blog-post/had-enough-eh https://www.science.org/content/blog-post/had-enough-eh Less than a week ago ANOTHER amyloid hypothesis drug failed a Phase III, this from Roche. There are at least three more drugs based on that in Phase III right now (Gantenerumab, Donanemab and Lecanemab). So the drugs that are getting to Phase III are still based on the amyloid hypothesis. Now note that drugs in Phase III are a lagging indicator, so the initial screening and phase 0 research might have changed direction, but the part of the iceberg sticking up out of the water is definitely still amyloid based.